The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EVGN | -30.77% | -98.67% | -57.8% | -92% |
| S&P | +13.95% | +78.35% | +12.25% | +420% |
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.
No news articles found for Evogene.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $312.00K | -82.6% |
| Gross Profit | -$126.00K | -243.2% |
| Gross Margin | -40.38% | -45.3% |
| Market Cap | $9.95M | -35.9% |
| Market Cap / Employee | $85.06K | 0.0% |
| Employees | 117 | 0.0% |
| Net Income | -$2,729.00K | 66.8% |
| EBITDA | -$2,434.00K | 64.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.63M | -50.3% |
| Accounts Receivable | $379.00K | -76.2% |
| Inventory | 2.1 | 45.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.85M | 585.9% |
| Short Term Debt | $675.00K | 61.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -28.77% | 19.3% |
| Return On Invested Capital | -789.10% | -705.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3,801.87K | 25.4% |
| Operating Free Cash Flow | -$3,790.58K | 23.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.92 | -1.96 | -2.34 | -2.80 | -154.95% |
| Price to Sales | 1.49 | 1.26 | 1.37 | 1.90 | -20.49% |
| Price to Tangible Book Value | -0.76 | -0.51 | -0.55 | -2.80 | 72.31% |
| Enterprise Value to EBITDA | -4.07 | -4.62 | -5.80 | -5.19 | 133.92% |
| Return on Equity | -228.9% | -331.9% | -311.0% | -655.0% | 363.36% |
| Total Debt | $2.50M | $2.59M | $2.66M | $2.52M | 267.35% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
